Loading...
•
Dec 31, 2023
Eton Q4 2023 Earnings Report
Eton reported a 109% year-over-year increase in product sales and royalty revenue, driven by ALKINDI SPRINKLE® and Carglumic Acid, and generated positive operating cash flow.
Key Takeaways
Eton Pharmaceuticals reported a strong fourth quarter, marked by a 109% increase in product sales and royalty revenue. The company achieved positive operating cash flow and saw favorable developments in its pipeline, including positive study results for ET-400 and ET-600.
Reported a 109% year-over-year increase in product sales and royalty revenue, reaching $7.3 million.
Achieved positive operating cash flow of $0.4 million.
ET-400 passed pivotal bioequivalence study, with NDA submission expected in Q2 2024.
ET-600 passed pilot bioequivalence study; pivotal study planned for the second half of 2024.
Eton
Eton
Eton Revenue by Segment
Revenue by Segment
Product Sales & Royalties Revenue
CapyFin.com Forward Guidance
Eton anticipates continued growth of product sales in 2024 and looks forward to submitting an NDA for ET-400 in the second quarter of this year and ET-600 early next year.
Positive Outlook
- Continued growth of product sales is anticipated in 2024.
- NDA submission for ET-400 is expected in Q2 2024.
- Potential FDA approval for ET-400 as early as Q1 2025.
- Pivotal study for ET-600 is planned for the second half of 2024, with potential NDA submission in early 2025.
- Ultra-rare disease product Nitisinone capsules launched in February 2024.